Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Adding a biologic to allergen immunotherapy increases treatment efficacy

Andrzej Bożek, Andreas Fischer, Agnieszka Bogacz-Piaseczynska, Giorgio Walter Canonica
ERJ Open Research 2023; DOI: 10.1183/23120541.00639-2022
Andrzej Bożek
1Clinical Department of Internal Diseases, Dermatology and Allergology, Medical University of Silesia, Katowice, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrzej Bożek
  • For correspondence: andrzej.bozek@sum.edu.pl
Andreas Fischer
2Outpatient Allergy Clinic, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Agnieszka Bogacz-Piaseczynska
1Clinical Department of Internal Diseases, Dermatology and Allergology, Medical University of Silesia, Katowice, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giorgio Walter Canonica
2Outpatient Allergy Clinic, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background The application of AIT in combination with biological agents has been found to increase both the safety and efficacy of the desensitization procedure in patients with food and insect venom allergy.

The aim of our study was to compare the effectiveness of allergen immunotherapy in patients with house dust mite (HDM) - driven asthma treated with and without omalizumab.

Materials and methods The study was a placebo-controlled, three-armed, randomized, parallel-group, multicentre trial that included 52 patients with HDM-driven asthma. Only patients with monosensitization to HDM were included. The study compared three patterns of therapy: omalizumab alone, house dust mite injection immunotherapy (HDM SCIT)+ omalizumab and SCIT alone. The main outcomes were evaluate the Asthma Control Questionnaire (ACQ) score, number of asthma exacerbations and reduction in the daily dose of inhaled steroids during 12 months of observation.

Results All variants of therapy led to significantly improved ACQ scores and reducted of asthma exacerbations in all study groups after 12 months of treatment. A statistically significant reduction in the daily doses of ICS in the group with omalizumab alone (650±150 mcg versus 500±50 mcg for p=0.003) or HDM-SCIT+omalizumab (550±250 mcg versus 375±75 for p=0.001) was observed, favoring the latter group.

Conclusion The efficacy of AIT for house - dust mite driven asthma is significantly increased by the combination of allergen vaccine with omalizumab.

Footnotes

This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.

This is a PDF-only article. Please click on the PDF link above to read it.

  • Received November 22, 2022.
  • Accepted December 19, 2022.
  • Copyright ©The authors 2023
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

PreviousNext
Back to top
Vol 9 Issue 2 Table of Contents
ERJ Open Research: 9 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Adding a biologic to allergen immunotherapy increases treatment efficacy
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Adding a biologic to allergen immunotherapy increases treatment efficacy
Andrzej Bożek, Andreas Fischer, Agnieszka Bogacz-Piaseczynska, Giorgio Walter Canonica
ERJ Open Research Jan 2023, 00639-2022; DOI: 10.1183/23120541.00639-2022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Adding a biologic to allergen immunotherapy increases treatment efficacy
Andrzej Bożek, Andreas Fischer, Agnieszka Bogacz-Piaseczynska, Giorgio Walter Canonica
ERJ Open Research Jan 2023, 00639-2022; DOI: 10.1183/23120541.00639-2022
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Pulmonary Artery Wedge Pressure and Left Ventricular End-Diastolic pressure during exercise in patients with dyspnea
  • Reference equations for breathlessness during incremental cycle exercise testing
  • Exercise intolerance in post-COVID19 survivors after hospitalization
Show more Original research article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society